Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | MMP9 | P14780 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dacarbazine SCHEMBL5560 | 1.00 | PAX8 (0.59) | PAX8LMNATSHRKDM4EALDH1A1 | |
| Dacarbazine SCHEMBL12591753 | 1.00 | PAX8 (0.59) | PAX8LMNATSHRKDM4EALDH1A1 | |
| Dacarbazine SCHEMBL6372 | 1.00 | PAX8 (0.59) | PAX8LMNATSHRKDM4EALDH1A1 | |
| Dacarbazine SCHEMBL28074492 | 0.98 | PAX8 (0.57) | PAX8LMNATSHRKDM4EALDH1A1 | |
| Dacarbazine SCHEMBL29042921 | 0.98 | PAX8 (0.57) | PAX8LMNATSHRKDM4EALDH1A1 | |
| Dacarbazine SCHEMBL28074490 | 0.98 | PAX8 (0.57) | PAX8LMNATSHRKDM4EALDH1A1 | |
| Dacarbazine SCHEMBL28090781 | 0.98 | PAX8 (0.57) | PAX8LMNATSHRKDM4EALDH1A1 | |
| Dacarbazine SCHEMBL28242658 | 0.98 | PAX8 (0.57) | PAX8LMNATSHRKDM4EALDH1A1 | |
| Dacarbazine SCHEMBL3957404 | 0.98 | PAX8 (0.57) | PAX8LMNATSHRKDM4EALDH1A1 | |
| Dacarbazine SCHEMBL28090782 | 0.98 | PAX8 (0.57) | PAX8LMNATSHRKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018081719-A1 | SMALL MOLECULE INHIBITORS OF NEK2 AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2018-05-03 | — | — | WO | disclosed |
| EP-3285583-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | The Regents of The University of Michigan (US) | 2018-02-28 | — | — | EP | disclosed |
| WO-2017165663-A1 | BIOMARKERS FOR CANCER ASSOCIATED WITH HEDGEHOG PATHWAY ACTIVITY AND RELATED USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2017-09-28 | — | — | WO | disclosed |
| EP-3111222-A1 | METHODS OF TREATING CANCER PATIENTS RESPONDING TO EZH2 INHIBITOR GSK126 | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-01-04 | — | — | EP | disclosed |
| WO-2016172218-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-10-27 | — | — | WO | disclosed |
| EP-2970965-A2 | DNAI FOR THE MODULATION OF GENES | Pronai Therapeutics, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2015128837-A1 | METHODS OF TREATING CANCER PATIENTS RESPONDING TO EZH2 INHIBITOR GSK126 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-09-03 | — | — | WO | disclosed |
| WO-2014144942-A2 | DNAI FOR THE MODULATION OF GENES | PRONAI THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-2491041-A2 | BIVALENT DIAZO BICYCLIC SMAC MIMETICS AND THE USES THEREOF | The Regents of the University of Michigan (US) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011050068-A2 | BIVALENT DIAZO BICYCLIC SMAC MIMETICS AND THE USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-04-28 | — | — | WO | disclosed |
| EP-1399140-A1 | BIOLOGICAL RESPONSE MODIFIER COMPOSITION AND USES THEREOF | Lorus Therapeutics Inc. (CA) | 2004-03-24 | — | — | EP | disclosed |
| EP-1333847-A1 | COMBINATION PREPARATION OF A BIOLOGICAL RESPONSE MODIDIER AND AN ANTICANCER AGENT AND USES THEREOF | Lorus Therapeutics Inc. (CA) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002102363-A1 | BIOLOGICAL RESPONSE MODIFIER COMPOSITION AND USES THEREOF | LORUS THERAPEUTICS INC. (CA) | 2002-12-27 | — | — | WO | disclosed |
| WO-2002038164-A1 | COMBINATION PREPARATION OF A BIOLOGICAL RESPONSE MODIFIER AND AN ANTICANCER AGENT AND USES THEREOF | LORUS THERAPEUTICS INC. (CA) | 2002-05-16 | — | — | WO | disclosed |